This suggests that the use of sCAR-T cells co-targeting IGF1R in addition to HER2 is a promising strategy for treating HER2+ breast cancers, showing enhanced cytotoxic activity and T cell activation in comparison to monospecific sCAR-T cells. Here, ERBB2 is linked to breast carcinoma.